GlassScriptPhysician profile
Efosa Ogiamien
NPI 1245640820
$5,442.38
in general payments reported to CMS, 2019-2025
27 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $1,004 · 2021: $783 · 2022: $887 · 2023: $307 · 2024: $761 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,279.34 | 2020-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Nevro Corp. | $1,230.62 | 2019-2024 | Senza |
| Medtronic, INC. | $833.65 | 2021-2025 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $450.99 | 2020-2024 | Relistor |
| Biotronik Nro, INC. | $331.74 | 2024-2025 | Prospera |
| Forte Bio-Pharma LLC | $217.38 | 2019-2022 | |
| Curonix LLC | $161.03 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbott Laboratories | $131.77 | 2020-2025 | Proclaim |
| Collegium Pharmaceutical, INC. | $109.30 | 2020-2024 | Belbuca |
| Horizon Therapeutics Plc | $90.30 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $65.46 | 2020 | |
| Novartis Pharmaceuticals Corporation | $63.20 | 2020-2021 | |
| Mdd US Operations, LLC | $59.76 | 2020 | |
| Zyla Life Sciences, INC. | $51.73 | 2020 | |
| Redhill Biopharma INC. | $51.56 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $45.23 | 2019-2020 | |
| Trevena, INC. | $35.09 | 2022-2023 | Olinvyk |
| Spinal Simplicity, LLC | $32.10 | 2022 | |
| Biodelivery Sciences International, INC. | $29.46 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $27.49 | 2023 | Seglentis |
| Almatica Pharma LLC | $25.62 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $25.14 | 2025 | |
| Virtus Pharmaceuticals LLC | $24.21 | 2021-2022 | |
| Pacira Therapeutics, INC. | $21.11 | 2019 | |
| Avanos Medical | $20.53 | 2024 | Generator |
| Globus Medical, INC. | $15.04 | 2025 | Senza |
| Heron Therapeutics, INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efosa Ogiamien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.